High Plasma Heparin Cofactor II Activity Is Associated with Reduced Incidence of In-Stent Restenosis after Percutaneous Coronary Intervention

Circulation

Volumn 109, Issue 4, 2004, Pages 481-486

  Takamori, Nobuyuki ^a   Azuma, Hiroyuki ^a   Kato, Midori ^a   Hashizume, Shunji ^a   Aihara, Ken Ichi ^a   Akaike, Masashi ^a   Tamura, Katsuya ^b   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Health Insurance Naruto Hospital   (Japan)

Author keywords

Angioplasty; Atherosclerosis; Cardiovascular diseases; Dermatan sulfate; Thrombin

Indexed keywords

DERMATAN SULFATE; HEPARIN COFACTOR II; PROTEIN INHIBITOR; THROMBIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RESTENOSIS; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; FEMALE; HEPARIN COFACTOR II; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; STENTS;

EID: 0842264178     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000109695.39671.37     Document Type: Article

References (35)

1. DiCorleto PE. Cellular mechanisms of atherogenesis. Am J Hypertens. 1993;6:314S-318S.
2. Wilensky RL, Pyles JM, Fineberg N. Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. Am Heart J. 1999;138:319-325.
3. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost. 1995;74:1209-1214.
4. Tammi M, Seppala PO, Lehtonen A, et al. Connective tissue components in normal and atherosclerotic human coronary arteries. Atherosclerosis. 1978;29:191-194.
5. Sie P, Dupouy D, Pichon J, et al. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet. 1985;2: 414-416.
6. Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet. 1985;2:413-414.
7. Blinder MA, Andersson TR, Abildgaard U, et al. Heparin cofactor IIOslo: mutation of Arg-189 to His decreases the affinity for dermatan sulfate. J Biol Chem. 1989;264:5128-5133.
8. Kanagawa Y, Shigekiyo T, Aihara K, et al. Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb Haemost. 2001;85:101-107.
9. Matsuo T, Kario K, Sakamoto S, et al. Hereditary heparin cofactor II deficiency and coronary artery disease. Thromb Res. 1992;65: 495-505.
10. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med. 2002;126:1394-1400.
11. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39: 183-193.
12. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
13. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224-233.
14. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol. 2001;38:645-652.
15. Kishi K, Hiasa Y, Suzuki N, et al. Predictors of recurrent restenosis after coronary stenting: an analysis of 197 patients. J Invasive Cardiol. 2002;14:187-191.
16. Sheiban I, Leonardo F, Rosano GM, et al. Predictors of long-term clinical outcome in patients undergoing multiple vessel stenting for coronary artery disease. Ital Heart J. 2000;1:480-486.
17. Imazu M, Sumii K, Yamamoto H, et al. Hyperinsulinemia as a risk factor for restenosis after coronary balloon angioplasty. Jpn Circ J. 2001;65:947-952.
18. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002;288:973-979.
19. Frystyk J, Ledet T, Moller N, et al. Cardiovascular disease and insulin-like growth factor I. Circulation. 2002;106:893-895.
20. He L, Vicente CP, Westrick RJ, et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109: 213-219.
21. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol. 1987;60: 20B-28B.
22. Kranzhofer R, Maraganore JM, Baciu R, et al. Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit. Cardiovasc Drugs Ther. 1999;13:429-434.
23. Wilcox JN, Blumenthal BF. Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. J Nutr. 1995;125:631S-638S.
24. Moreno PR, Palacios IF, Leon MN, et al. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol. 1999;84:462-466, A9.
25. Buchanan MR, Brister SJ. Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment: relative effects of heparin and dermatan sulphate. Thromb Res. 1998;91:157-167.
26. Yamanaga K, Yuuki T, Tsukada M, et al. Heparin cofactor II inhibits thrombus formation in a rat thrombosis model. Thromb Res. 2000;98: 95-101.
27. Hennan JK, Hong TT, Shergill AK, et al. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther. 2002;301:1151-1156.
28. Lee HS, Tardif JC, Harel F, et al. Effects of plaque composition on vascular remodelling after angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol. 2002;18:271-275.
29. Kamishirado H, Inoue T, Mizoguchi K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 2002;144:303-308.
30. Muller R, Bullesfeld L, Gerckens U, et al. State of treatment of coronary artery disease by drug releasing stents [in German]. Herz. 2002;27:508-513.
31. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
32. Peters S, Gotting B, Trummel M, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol. 2001;13:93-97.
33. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867-1873.
34. Presbitero P, Asioli M. Drug-eluting stents do they make the difference? [in Italian]. Minerva Cardioangiol. 2002;50:431-442.
35. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002;106:1949-1956.